Nataliya Andreychuk, the co-founder and CEO of Viseven, reveals her personal battle against breast cancer. Her story is a testament to enduring strength, tenacity, and sincere commitment to make a genuine difference in patients’ lives.
In this article, Ross Errington, Head of Drug Product Development at Recipharm, explores the growth of the biosimilar market and its role in driving the demand for biologic redevelopment, focusing on the move towards inhaled biologics as a solution.
The biopharma industry has made minor strides toward improved resilience, but it’s not enough to meet future global demand for novel therapeutics. However, Ludovi Brellier, shows how to get there.
The COVID-19 pandemic was an eye opener for the world on how quickly diseases and pathogens can emerge and spread globally. AI could give us the edge over the next global health threat, says Jeremy Skillington, PhD, CEO of Poolbeg Pharma.
In this article, we will unravel the mysteries of Materiovigilance and dive into how it plays a crucial role in the safety of SaMD. We'll explore the challenges, the strategies, and even how modern tools like Artificial Intelligence are changing.
Oxford BioDynamics and Bupa, the UK’s leading health insurer, announce a strategic agreement to give Bupa patients access to OBD’s EpiSwitch CiRT (Checkpoint inhibitor Response Test).
Paul Davis, Managing Director of Wanner International takes a deep dive into a technology which is widely used by the oil and gas and petrochem industries looking at how it is providing a solution to challenges in pharmaceutical manufacture.
Tom Cowen, Head of Vertical Strategy, Healthcare & Life Sciences at Conga explores what happens when price transparency and government involvement goes too far and ways to prepare for this.
To develop cannabis products that can both enhance the quality of life of cannabis users and comply with current and future regulations, first we must understand what cannabis is, how people use it, and how it affects the human body and mind.
Cristina Grigore, Technical Proposals Manager, Lonza Ltd discusses the evolving landscape for the role CDMOs play as essential partners with biotech for developing new medicines.
Justin Wilson, a partner and life sciences specialist at European intellectual property firm, Withers & Rogers explores why M&A are pushing to secure a slice of the gene therapy opportunity.
Stephan Ohnmacht and Werner Engelbrecht explore EMA’s vision of a single source of truth for clinical trial information forces a major shift in how companies collect and store trial data and documents.
